全文获取类型
收费全文 | 207459篇 |
免费 | 39123篇 |
国内免费 | 6978篇 |
专业分类
耳鼻咽喉 | 5621篇 |
儿科学 | 5915篇 |
妇产科学 | 2946篇 |
基础医学 | 10169篇 |
口腔科学 | 2650篇 |
临床医学 | 34355篇 |
内科学 | 55650篇 |
皮肤病学 | 7853篇 |
神经病学 | 17992篇 |
特种医学 | 8478篇 |
外国民族医学 | 52篇 |
外科学 | 46716篇 |
综合类 | 11296篇 |
现状与发展 | 91篇 |
一般理论 | 5篇 |
预防医学 | 11069篇 |
眼科学 | 5139篇 |
药学 | 7649篇 |
38篇 | |
中国医学 | 3455篇 |
肿瘤学 | 16421篇 |
出版年
2023年 | 5742篇 |
2022年 | 2627篇 |
2021年 | 5997篇 |
2020年 | 8539篇 |
2019年 | 4337篇 |
2018年 | 9521篇 |
2017年 | 9337篇 |
2016年 | 10281篇 |
2015年 | 11291篇 |
2014年 | 19028篇 |
2013年 | 18599篇 |
2012年 | 10195篇 |
2011年 | 10581篇 |
2010年 | 13349篇 |
2009年 | 16525篇 |
2008年 | 8979篇 |
2007年 | 7084篇 |
2006年 | 9509篇 |
2005年 | 6755篇 |
2004年 | 4934篇 |
2003年 | 3872篇 |
2002年 | 3608篇 |
2001年 | 5137篇 |
2000年 | 4408篇 |
1999年 | 4820篇 |
1998年 | 4598篇 |
1997年 | 4326篇 |
1996年 | 4023篇 |
1995年 | 3837篇 |
1994年 | 2573篇 |
1993年 | 1949篇 |
1992年 | 1911篇 |
1991年 | 1826篇 |
1990年 | 1441篇 |
1989年 | 1494篇 |
1988年 | 1324篇 |
1987年 | 1081篇 |
1986年 | 1094篇 |
1985年 | 891篇 |
1984年 | 639篇 |
1983年 | 574篇 |
1982年 | 552篇 |
1981年 | 434篇 |
1980年 | 373篇 |
1979年 | 348篇 |
1978年 | 343篇 |
1977年 | 410篇 |
1975年 | 284篇 |
1972年 | 282篇 |
1970年 | 257篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
91.
92.
93.
94.
95.
96.
97.
98.
Cheryl L. Rock PhD RD Cynthia A. Thomson PhD RD Kristen R. Sullivan MS MPH Carol L. Howe MD MLS Lawrence H. Kushi ScD Bette J. Caan DrPH Marian L. Neuhouser PhD RD Elisa V. Bandera MD PhD Ying Wang PhD Kimberly Robien PhD RD Karen M. Basen-Engquist PhD MPH Justin C. Brown PhD Kerry S. Courneya PhD Tracy E. Crane PhD RDN David O. Garcia PhD FACSM Barbara L. Grant MS RDN CSO FAND Kathryn K. Hamilton MA RDN CSO CDN FAND Sheri J. Hartman PhD Stacey A. Kenfield ScD Maria Elena Martinez PhD Jeffrey A. Meyerhardt MD MPH Larissa Nekhlyudov MD MPH Linda Overholser MD Alpa V. Patel PhD Bernardine M. Pinto PhD Mary E. Platek PhD RD CDN Erika Rees-Punia PhD MPH Colleen K. Spees PhD MEd RD LD FAND Susan M. Gapstur PhD Marjorie L. McCullough ScD RD 《CA: a cancer journal for clinicians》2022,72(3):230-262
The overall 5-year relative survival rate for all cancers combined is now 68%, and there are over 16.9 million survivors in the United States. Evidence from laboratory and observational studies suggests that factors such as diet, physical activity, and obesity may affect risk for recurrence and overall survival after a cancer diagnosis. The purpose of this American Cancer Society guideline is to provide evidence-based, cancer-specific recommendations for anthropometric parameters, physical activity, diet, and alcohol intake for reducing recurrence and cancer-specific and overall mortality. The audiences for this guideline are health care providers caring for cancer survivors as well as cancer survivors and their families. The guideline is intended to serve as a resource for informing American Cancer Society programs, health policy, and the media. Sources of evidence that form the basis of this guideline are systematic literature reviews, meta-analyses, pooled analyses of cohort studies, and large randomized clinical trials published since 2012. Recommendations for nutrition and physical activity during cancer treatment, informed by current practice, large cancer care organizations, and reviews of other expert bodies, are also presented. To provide additional context for the guidelines, the authors also include information on the relationship between health-related behaviors and comorbidities, long-term sequelae and patient-reported outcomes, and health disparities, with attention to enabling survivors' ability to adhere to recommendations. Approaches to meet survivors' needs are addressed as well as clinical care coordination and resources for nutrition and physical activity counseling after a cancer diagnosis. 相似文献
100.
Tie Zhou Shengfei Qin Weidong Xu Shouyan Tang Guanghua Chen Song Li Jianguo Hou Xu Gao Guowei Shi Zhongquan Sun Jie Jin Lijun Chen Weibing Sun Ben Liu Jingen Wang Qinggui Meng Dongwen Wang Zhiquan Hu Dalin He Yong Yang Xishuang Song Cheng Fu Yinhuai Wang Dingwei Ye Wei Zhang 《International journal of cancer. Journal international du cancer》2023,153(4):792-802
We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177). 相似文献